RVL Pharma Issues Interim Q2 Sales From Its Droopy Eye Treatment

  • RVL Pharmaceuticals plc RVLP announced preliminary Q2 FY22 sales from Upneeq of $8.4 million, up 42% sequentially.
  • Upneeq (oxymetazoline hydrochloride ophthalmic solution) is an approved ophthalmic solution for blepharoptosis or droopy eyelids.
  • The company also announced that from February through June of 2022, it had received orders from approximately 2,200 cumulative unique medical aesthetics practices. 
  • RVL Pharma also reaffirmed its Q4 Upneeq sales guidance of $20 million - $25 million.
  • Related: Osmotica Pharma Announces Rebranding As RVL Pharma, Issues Q4 Sales Outlook.
  • "As planned and previously announced, we expect to significantly expand our medical aesthetics salesforce by mid to late July and believe that we are well-positioned to build on our momentum and achieve our fourth quarter 2022 net sales projection," said CEO Brian Markison.
  • Price Action: RVLP shares closed 4.93% higher at $1.49 on Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechEarningsNewsPenny StocksGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!